Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Fulgent Genetics
(NASDAQ:FLGT)
Intraday
$20.10
0.07
[0.35%]
After-Hours
$20.10
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$20.10
0.07
[0.35%]
At close: Apr 26
$20.10
0
[0.00%]
After Hours: 4:20PM EDT
Get Report
Watch
Q1 2024 Earnings in 7 days from now on Fri May 3rd, before the market open
Conference call scheduled in 7 days at 8:30 AM
Click to view the webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Fulgent Genetics Stock (NASDAQ:FLGT)
Fulgent Genetics Stock (NASDAQ: FLGT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, March 06, 2024
Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $25
Benzinga Newsdesk
-
Mar 6, 2024, 9:31AM
Wednesday, February 28, 2024
Fulgent Genetics shares are trading lower after the company reported Q4 financial results and issued FY24 guidance below estimates.
Benzinga Newsdesk
-
Feb 28, 2024, 12:07PM
Fulgent Genetics Expects 2024 Core Revenue of Approximately $280M Versus Consensus Of $294.25M, With Adjusted EPS Loss Of Approximately $(1.05) Versus Consensus Of $(0.95)
Benzinga Newsdesk
-
Feb 28, 2024, 7:05AM
Fulgent Genetics Q4 Adjusted EPS $0.28 May Not Be Comparable To $(0.29) Estimate, Sales $70.50M Beat $66.32M Estimate
Benzinga Newsdesk
-
Feb 28, 2024, 7:02AM
Earnings Scheduled For February 28, 2024
Benzinga Insights
-
Feb 28, 2024, 6:24AM
Friday, February 09, 2024
CooperSurgical Partners With Fulgent Genetics To Launch Genetic Screening Panels
Benzinga Newsdesk
-
Feb 9, 2024, 8:38AM
Thursday, December 07, 2023
UBS Initiates Coverage On Fulgent Genetics with Neutral Rating, Announces Price Target of $35
Benzinga Newsdesk
-
Dec 7, 2023, 6:06AM
Friday, November 03, 2023
Fulgent Genetics shares are trading higher after the company reported better-than-expected Q3 revenue results and issued FY23 guidance.
Benzinga Newsdesk
-
Nov 3, 2023, 12:27PM
Fulgent Sees FY23 Core Revenue $260M Vs $260.66M Estimate, Adj. EPS $(0.95) Vs $(1.09) Estimate
Benzinga Newsdesk
-
Nov 3, 2023, 7:27AM
Earnings Scheduled For November 3, 2023
Benzinga Insights
-
Nov 3, 2023, 7:12AM
Fulgent Q3 2023 EPS $(0.39) Misses $(0.33) Estimate, Revenue $66M Beats $63.4M Estimate
Benzinga Newsdesk
-
Nov 3, 2023, 7:04AM
Thursday, November 02, 2023
Earnings Preview: Fulgent Genetics
Benzinga Insights
-
Nov 2, 2023, 1:00PM
Monday, October 16, 2023
Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $28
Benzinga Newsdesk
-
Oct 16, 2023, 1:25PM
Wednesday, October 04, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Oct 4, 2023, 12:01PM
Monday, October 02, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Oct 2, 2023, 1:00PM
Friday, September 29, 2023
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
-
Sep 29, 2023, 1:35PM
Thursday, September 28, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 28, 2023, 2:32PM
Thursday, September 21, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 21, 2023, 12:08PM
Friday, August 04, 2023
Why Is Fulgent Genetics Stock Moving Higher Today?
Vandana Singh
-
Aug 4, 2023, 1:20PM
Fulgent Sees Q3 FY23 Sales Of Approximately $65M Vs. Consensus Of $62.84M
Benzinga Newsdesk
-
Aug 4, 2023, 7:11AM
Fulgent Revises FY23 Revenue Guidance To $260M Vs. Consensus Of $255.94M And Prior Guidance Of $250M, It Forecasts Adjusted EPS Of $(0.95) Vs. Consensus Of $(1.23) And Prior Guidance Of $(1.25)
Benzinga Newsdesk
-
Aug 4, 2023, 7:10AM
Fulgent Genetics Q2 Adjusted EPS $(0.08) Beats $(0.33) Estimate, Sales $67.85M Beat $62.68M Estimate
Benzinga Newsdesk
-
Aug 4, 2023, 7:01AM
Earnings Scheduled For August 4, 2023
Benzinga Insights
-
Aug 4, 2023, 5:30AM
Thursday, August 03, 2023
Earnings Outlook For Fulgent Genetics
Benzinga Insights
-
Aug 3, 2023, 1:02PM
Friday, May 19, 2023
Fulgent Genetics Earnings Perspective: Return On Capital Employed
Benzinga Insights
-
May 19, 2023, 10:47AM
Friday, May 05, 2023
Fulgent Genetics shares are trading higher after the company reported better-than-expected Q1 adjusted EPS and sales results.
Benzinga Newsdesk
-
May 5, 2023, 11:18AM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
May 5, 2023, 9:06AM
Fulgent Genetics: Q1 Earnings Insights
Benzinga Insights
-
May 5, 2023, 7:05AM
Fulgent Genetics Q1 Adjusted EPS $(0.22) Beats $(0.43) Estimate, Sales $66.17M Beat $60.05M Estimate
Benzinga Newsdesk
-
May 5, 2023, 7:05AM
Earnings Scheduled For May 5, 2023
Benzinga Insights
-
May 5, 2023, 5:59AM
Thursday, May 04, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
May 4, 2023, 12:29PM
Preview: Fulgent Genetics's Earnings
Benzinga Insights
-
May 4, 2023, 12:03PM
Monday, April 03, 2023
5 Value Stocks To Watch In The Healthcare Sector
Benzinga Insights
-
Apr 3, 2023, 10:43AM
Monday, March 06, 2023
Looking Into Fulgent Genetics's Return On Capital Employed
Benzinga Insights
-
Mar 6, 2023, 9:46AM
Thursday, March 02, 2023
Credit Suisse Maintains Outperform on Fulgent Genetics, Lowers Price Target to $45
Benzinga Newsdesk
-
Mar 2, 2023, 6:42AM
Tuesday, February 28, 2023
Fulgent Genetics Sees Q1 Total Revenue $56M vs $60.92M Est.; Sees FY23 Adj. EPS $(1.25) vs $(2.18) Est., Total Revenue ~$240M vs $260.75M Est.
Bill Haddad
-
Feb 28, 2023, 4:52PM
Fulgent Genetics Q4 EPS $(0.48) Beats $(0.56) Estimate, Sales $67.70M Beat $59.57M Estimate
Bill Haddad
-
Feb 28, 2023, 4:51PM
Earnings Scheduled For February 28, 2023
Benzinga Insights
-
Feb 28, 2023, 4:34AM
Friday, January 06, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Jan 6, 2023, 11:30AM
Tuesday, December 20, 2022
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Dec 20, 2022, 11:55AM
Monday, December 19, 2022
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Dec 19, 2022, 12:40PM
Thursday, December 08, 2022
Fulgent Genetics, Inc. shares are trading lower after Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target from $65 to $40.
Benzinga Newsdesk
-
Dec 8, 2022, 11:51AM
Where Fulgent Genetics Stands With Analysts
Benzinga Insights
-
Dec 8, 2022, 10:03AM
Piper Sandler Downgrades Fulgent Genetics to Neutral, Lowers Price Target to $40
Benzinga Newsdesk
-
Dec 8, 2022, 5:14AM
Monday, December 05, 2022
5 Value Stocks In The Healthcare Sector
Benzinga Insights
-
Dec 5, 2022, 9:43AM
Thursday, December 01, 2022
Fulgent Genetics's Return on Invested Capital Insights
Benzinga Insights
-
Dec 1, 2022, 9:50AM
Wednesday, November 23, 2022
On Nov 18, 2022, Fulgent Genetics Received A Letter From Nasdaq For Being No Longer In Compliance With The Audit Committee Requirements
Benzinga Newsdesk
-
Nov 23, 2022, 4:14PM
Friday, November 18, 2022
4 Analysts Have This to Say About Fulgent Genetics
Benzinga Insights
-
Nov 18, 2022, 12:04PM
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Benzinga Insights
-
Nov 18, 2022, 11:58AM
Benzinga Pro's Top 5 Stocks To Watch For Friday, November 18, 2022: ZM, SAM, PRVB, FLGT, STKH
Benzinga Newsdesk
-
Nov 18, 2022, 9:15AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch